Oral Contraceptives and Hypertensive Disease: A Cybernetic Overview

Oral contraceptives and hypertensive disease: a cybernetic overview.

Oral contraceptives and thromboembolic disease.

Oral contraceptives after liver disease.

Administration of oral contraceptives to 10 women was started two weeks after the normalization of the serum enzyme activities in the convalescent period of viral hepatitis, and to five women eight weeks after an operation of obstructive jaundice. Routine liver function tests were performed at intervals of two weeks for two to three months. The liver function tests stayed within normal limits d...

Oral Contraceptives

Current low dose OCs are highly effective with an excellent safety profile and many associated health benefits No single product has been shown to be superior in efficacy, safety or tolerability There is no "one size fits all" OC; different women may require different formulations Smoking particularly after age 35 with concurrent OC use greatly increases cardiovascular and thrombotic risks Age ...

Oral contraceptives and exercise.

A laboratory study was undertaken with volunteer females (aged 20-25) to determine the effect of OCs (oral contraceptives) on hematologic and metabolic variables during exercise. 5 of the women studied were naturally cycling and 7 were taking OCs. The women worked at 2 workloads on a bicycle ergometer at 50% and 90% of their maximal aerobic capacity during 3 different phases of their menstrua...